We assumed that genetic variability of CSF1 may modify amyloid deposition and neurodegeneration in the human brain and thereby the risk for Alzheimer's disease. To test this hypothesis we conducted a genetic case-control association study in a series of n = 327 individuals (183 healthy control subjects and 144 cases of sporadic AD, sample 2, table 1 ) from Switzerland. Diagnoses were made according to the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Associations (NINCDS-ADRDA) criteria for probable AD. Dementia and memory deficits in control subjects were excluded by neuropsychological testing, consisting of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropsychological test battery and the Mini-Mental State Examination (MMSE). The sample is characterized in table 1 . The local ethics committee approved the study, and informed consent was obtained from all participants prior to the investigation.
The human CSF1 gene maps to chromosome 1p21-p13, ϳ 4.3 cM off the peak marker D1S1678 of a region previously linked to AD [16] . It comprises 18,898 bp (base pairs 110165499-1101843397 of the chromosomal sequence) with 10 exons and encodes a 554-amino-acid protein. To span the whole locus we used 1 marker upstream (rs3093054) and 1 marker downstream (rs756325) of the gene. We genotyped rs1058885 (T/C, Leu/Pro) to tag the highly variable exon 6, which harbours 6 of 8 described non-synonymous CSF1 single nucleotide polymorphisms (SNPs) within a sequence of ϳ 470 bp. Information on SNPs was derived from the NCBI SNP database (http://www.ncbi.nlm.nih.gov/SNP). Genotypes were determined from genomic DNA by Pyrosequencing TM . The following oligonucleotides were used for PCR and sequencing: rs1058885, forward AGGC-TCTCC CAGGATCTCAT, reverse biotin-TTCACTTG-CTGG TCC TCCTT, sequencing CCCAGGATCTCAT-CAC; rs3093054, forward biotin-GGAGGGTGGAG-AGAAGAACA, reverse AGTGGGACTTGCAGCGTCT, sequencing GGATCTGCTTGATGTGG; rs756325, forward biotin-TTCCTCCCCTCAAAAGGATT, reverse GGGTCACAAAGGACTCAAGC, sequencing CCTG-GTGGATTTAGGG. The investigated SNPs and their haplotypes are characterized in Sample 1 was used for all 3 investigated SNPs. Sample 2 includes sample 1 and was used only for rs1058885. Results are those of healthy control subjects/AD patients. None of the 3 markers or their haplotypes were associated with AD risk in a sub-sample of n = 185 individuals (sample 1, table 1 ), using 2 tests and forward unconditional logistic regression controlling for apolipoprotein E ( APOE ), age and sex ( tables 2 , 3 ). Because linkage to AD on chromosome 1 was predominantly observed in APOE 4 allele carriers [16] , we also stratified for APOE 4. In the 4-positive subset (n = 71) we found a borderline significance of rs1058885 (linear-by-linear 2 test, p = 0.03). To corroborate this observation we increased the sample size to n = 327 (sample 2, table 1 ). In the enlarged sample the effect was disrupted (linear-by-linear 2 test, p = 0.06), and rs1058885 also remained negative in the combined sample of APOE-4 -allele-positive (n = 140) and -negative participants ( table 3 ) .
Based on functional and positional criteria, CSF1 was selected as a candidate risk gene for AD. In summary our data do not support the hypothesis that genetic variability of CSF1 may contribute to the risk for sporadic AD in the investigated population. We emphasize that the present study does not exclude CSF1 as an AD susceptibility gene because of 2 main reasons. (I) Low statistical power: the relative risk associated with the minor alleles of the 3 SNPs that would have been detectable with 80% power at a significance level of p = 0.05 (n = 185) was between 0.13 and 0.37 or 2.47 and 3.10, respectively. Conversely, the power to reach a significance level of p = 0.05 for the observed relative risks was between 4 and 11%. (II) Low resolution: with 3 SNPs across the CSF1 locus the resolution was about 9 kb. The linkage disequilibrium and allele frequencies of the investigated markers did not capture the whole genetic variability of CSF1 .
CSF1 may play an important role in the regulation of the microglial response to amyloid pathology in AD. Over-expression of the CSF1 receptor facilitates the phagocytosis of antibody-opsonized A ␤ by microglial cells [17] , which is a potentially important mechanism in immune therapy of AD. Future studies could assess if CSF1 SNPs are associated with responsiveness to active or passive A ␤ vaccination, if CSF1 may serve as a biomarker to monitor the microglial response to this treatment, or if CSF1 has a therapeutic potential alone or as an adjuvant in the immune therapy of AD. There was no significant association of the investigated SNPs with the diagnosis of AD. Statistics refer to the comparison of the 2 alleles of the respective SNPs between the AD and the HCS group. p values in brackets were obtained by forward unconditional logistic regression, correcting for age, sex, presence or absence of at least 1 APOE 4 allele and the respective other CSF1 SNPs. HCS = Healthy control subjects.
